NCT05960565 is a Phase 2 clinical trial of Glucagon in Type 1 Diabetes, sponsored by St. Olavs Hospital.

Who is sponsoring NCT05960565?

NCT05960565 is sponsored by St. Olavs Hospital.

What drugs are being tested in NCT05960565?

Interventions in NCT05960565: Glucagon.

What condition does NCT05960565 study?

NCT05960565 studies Type 1 Diabetes.

Is NCT05960565 still recruiting?

NCT05960565 is currently terminated. Last updated 13 June 2025.

Last reviewed 2025-06-13 · How we verify

NCT05960565

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glucagon Enhanced Insulin Absorption in Diabetes Mellitus Type 1

Terminated Phase 2 Last updated 13 June 2025

What this trial tests

Phase 2 trial testing Glucagon in Type 1 Diabetes in 9 participants. Terminated before completion.

Timeline

22 December 2023

Primary endpoint
22 December 2023

22 December 2023

Quick facts

Lead sponsor	St. Olavs Hospital
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	22 December 2023
Primary completion	22 December 2023
Estimated completion	22 December 2023
Sites	1 location across Norway

Drugs / interventions tested

Glucagon (GLUCAGON) — full drug profile →

Conditions studied

Type 1 Diabetes — all drugs for Type 1 Diabetes →

Sponsor

St. Olavs Hospital

Who can join

Adults 18 to 70, any sex, with Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will study the effect of microdoses of glucagon at the site of subcutaneous insulin injection. The investigators have unpublished data from anesthetized pigs indicating a major enhancement of insulin absorption.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Glucagon

Trials testing the same drug.

NCT06558422 — Human Models of Selective Insulin Resistance: Pancreatic Clamp · Phase 1 · not yet recruiting
NCT06872060 — The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance. · NA · not yet recruiting
NCT06424106 — Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes · NA · recruiting
NCT06921824 — Investigating the Acute Effects of Increasing Glucagon Exposure in Healthy Participants · NA · completed
NCT06588504 — Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults · Phase 1 · completed

Other recruiting trials for Type 1 Diabetes

Currently open trials in the same condition.

NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting

Other St. Olavs Hospital trials

Trials by the same sponsor.

NCT07331766 — Collaboratory Treatment Pathway for Chronic Pain Patients. · NA · enrolling by invitation
NCT07305025 — Pelvic Pain Electro-Acupuncture · NA · not yet recruiting
NCT07245264 — Adjuvant Tranexamic Acid (TXA) Versus Surgery Alone for Adult Patients With Chronic Subdural Hematoma (CSDH) · Phase 2, PHASE3 · recruiting
NCT07180433 — Piloting 18F-FAPI PET/MRI for Applications in Breast Cancer · NA · not yet recruiting
NCT06854861 — Premixed Glucagon/Insulin Solution for Faster Insulin Absorption in Type 1 Diabetes · Phase 1, PHASE2 · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05960565 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by St. Olavs Hospital
Last refreshed: 13 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05960565.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing